# Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers

> **NCT05131919** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 25 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05131919
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-22
- **Primary completion:** 2030-07
- **Final completion:** 2031-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05131919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05131919, "Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05131919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*